Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog® Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT03874715 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03874715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03874715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog® Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
March 11, 2019
Completion date
July 8, 2020
Enrollment
210 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus